{"hands_on_practices": [{"introduction": "The core benefit of maternal immunization is the transfer of protective antibodies to the fetus, creating a shield of passive immunity during the vulnerable early months of life. However, this protection is transient. This exercise [@problem_id:4452698] allows you to apply first-order kinetic principles to quantify the decay of maternally derived antibodies in an infant, providing a clear, mathematical understanding of the \"window of vulnerability\" and the rationale behind the timing of the primary infant vaccine series.", "problem": "A pregnant patient receives Tetanus, Diphtheria, and acellular Pertussis (Tdap) at gestational age $28$ weeks. Two weeks later (gestational age $30$ weeks), her serum anti-pertussis Immunoglobulin G (IgG) concentration is measured at $18.0$ International Units per milliliter. Assume the following well-tested facts: (i) Immunoglobulin G (IgG) elimination in both mother and infant follows first-order kinetics governed by a constant proportional decay rate; (ii) the half-life of maternal anti-pertussis IgG after boosting is $50$ days; (iii) the half-life of infant anti-pertussis IgG is $36$ days; (iv) the cord:maternal concentration transfer ratio at delivery is $R = 1.3$; (v) delivery occurs at gestational age $39$ weeks; and (vi) the protective threshold for infant pertussis IgG is $T = 1.0$ International Units per milliliter. Use $7$ days per week to convert half-lives to weeks where needed. Starting from the definition of first-order decay and the definition of half-life, derive and compute the postnatal age $t^{\\ast}$ (in weeks) at which the infant’s anti-pertussis IgG concentration first falls below the protective threshold $T$. Round your answer to $3$ significant figures. Express the age in weeks.", "solution": "The elimination of Immunoglobulin G (IgG) is stated to follow first-order kinetics. The concentration $C$ of a substance undergoing first-order decay at time $t$ is given by the equation:\n$$C(t) = C_0 \\exp(-kt)$$\nwhere $C_0$ is the initial concentration and $k$ is the decay rate constant. The decay constant $k$ is related to the half-life $t_{1/2}$ by the definition of half-life, $C(t_{1/2}) = \\frac{1}{2} C_0$.\n$$\\frac{1}{2} C_0 = C_0 \\exp(-k t_{1/2}) \\implies \\frac{1}{2} = \\exp(-k t_{1/2}) \\implies \\ln\\left(\\frac{1}{2}\\right) = -k t_{1/2}$$\nThis gives the relationship:\n$$k = \\frac{\\ln(2)}{t_{1/2}}$$\n\nWe must first determine the maternal anti-pertussis IgG concentration at the time of delivery. The time interval between the measurement at gestational age $30$ weeks and delivery at $39$ weeks is $\\Delta t_m = 39 - 30 = 9$ weeks.\n\nThe maternal half-life is given as $t_{1/2,m} = 50$ days. Since the final answer is requested in weeks, we convert this to weeks using the provided conversion of $7$ days per week:\n$$t_{1/2,m} = \\frac{50}{7} \\text{ weeks}$$\nThe corresponding maternal decay constant, $k_m$, is:\n$$k_m = \\frac{\\ln(2)}{t_{1/2,m}} = \\frac{\\ln(2)}{50/7} = \\frac{7 \\ln(2)}{50} \\text{ weeks}^{-1}$$\nThe maternal IgG concentration at $30$ weeks is $C_{m,30} = 18.0$ IU/mL. The concentration at delivery, $C_{m,del}$, after $\\Delta t_m = 9$ weeks, is:\n$$C_{m,del} = C_{m,30} \\exp(-k_m \\Delta t_m) = 18.0 \\exp\\left(-\\frac{7 \\ln(2)}{50} \\times 9\\right)$$\n\nNext, we calculate the infant's IgG concentration at birth (postnatal age $t=0$). This is given by the maternal concentration at delivery multiplied by the cord:maternal concentration transfer ratio, $R = 1.3$.\n$$C_{i,0} = R \\times C_{m,del} = 1.3 \\times \\left[ 18.0 \\exp\\left(-\\frac{63 \\ln(2)}{50}\\right) \\right]$$\n\nNow, we model the decay of IgG in the infant. The infant half-life is $t_{1/2,i} = 36$ days. Converting to weeks:\n$$t_{1/2,i} = \\frac{36}{7} \\text{ weeks}$$\nThe infant decay constant, $k_i$, is:\n$$k_i = \\frac{\\ln(2)}{t_{1/2,i}} = \\frac{\\ln(2)}{36/7} = \\frac{7 \\ln(2)}{36} \\text{ weeks}^{-1}$$\nThe infant's IgG concentration at a postnatal age of $t$ weeks is given by:\n$$C_i(t) = C_{i,0} \\exp(-k_i t)$$\n\nWe need to find the postnatal age $t^{\\ast}$ at which the infant's IgG concentration falls to the protective threshold, $T = 1.0$ IU/mL. We set $C_i(t^{\\ast}) = T$ and solve for $t^{\\ast}$.\n$$T = C_{i,0} \\exp(-k_i t^{\\ast})$$\nSolving for $t^{\\ast}$:\n$$\\frac{T}{C_{i,0}} = \\exp(-k_i t^{\\ast})$$\n$$\\ln\\left(\\frac{T}{C_{i,0}}\\right) = -k_i t^{\\ast}$$\n$$t^{\\ast} = -\\frac{1}{k_i} \\ln\\left(\\frac{T}{C_{i,0}}\\right) = \\frac{1}{k_i} \\ln\\left(\\frac{C_{i,0}}{T}\\right)$$\nSubstituting the expression for $C_{i,0}$:\n$$t^{\\ast} = \\frac{1}{k_i} \\ln\\left(\\frac{R \\cdot C_{m,del}}{T}\\right) = \\frac{1}{k_i} \\ln\\left(\\frac{R \\cdot C_{m,30} \\exp(-k_m \\Delta t_m)}{T}\\right)$$\nUsing the property of logarithms $\\ln(ab) = \\ln(a) + \\ln(b)$ and $\\ln(\\exp(x)) = x$:\n$$t^{\\ast} = \\frac{1}{k_i} \\left[ \\ln\\left(\\frac{R \\cdot C_{m,30}}{T}\\right) - k_m \\Delta t_m \\right]$$\nNow, we substitute the expressions for $k_i$ and $k_m$ in terms of their half-lives:\n$$t^{\\ast} = \\frac{t_{1/2,i}}{\\ln(2)} \\left[ \\ln\\left(\\frac{R \\cdot C_{m,30}}{T}\\right) - \\frac{\\ln(2)}{t_{1/2,m}} \\Delta t_m \\right]$$\n$$t^{\\ast} = \\frac{t_{1/2,i}}{\\ln(2)} \\ln\\left(\\frac{R \\cdot C_{m,30}}{T}\\right) - \\frac{t_{1/2,i}}{t_{1/2,m}} \\Delta t_m$$\nWe can now substitute the given numerical values into this final analytical expression.\n$R = 1.3$, $C_{m,30} = 18.0$, $T = 1.0$, $\\Delta t_m = 9$ weeks, $t_{1/2,i} = \\frac{36}{7}$ weeks, $t_{1/2,m} = \\frac{50}{7}$ weeks.\nThe ratio of half-lives is $\\frac{t_{1/2,i}}{t_{1/2,m}} = \\frac{36/7}{50/7} = \\frac{36}{50} = 0.72$.\n$$t^{\\ast} = \\frac{36/7}{\\ln(2)} \\ln\\left(\\frac{1.3 \\times 18.0}{1.0}\\right) - \\frac{36}{50} \\times 9$$\n$$t^{\\ast} = \\frac{36}{7 \\ln(2)} \\ln(23.4) - 6.48$$\nUsing numerical values for the logarithms, $\\ln(2) \\approx 0.693147$ and $\\ln(23.4) \\approx 3.152736$.\n$$t^{\\ast} \\approx \\frac{36}{7 \\times 0.693147} \\times 3.152736 - 6.48$$\n$$t^{\\ast} \\approx \\frac{36}{4.85203} \\times 3.152736 - 6.48$$\n$$t^{\\ast} \\approx 7.41957 \\times 3.152736 - 6.48$$\n$$t^{\\ast} \\approx 23.3878 - 6.48 = 16.9078 \\text{ weeks}$$\nRounding the result to $3$ significant figures gives $16.9$ weeks.", "answer": "$$\n\\boxed{16.9}\n$$", "id": "4452698"}, {"introduction": "While some immunization scenarios are straightforward, clinical practice often presents ambiguous data requiring careful interpretation. This practice [@problem_id:4452674] delves into a common diagnostic challenge: managing a pregnant patient with an uncertain hepatitis B serological profile. By working through this case, you will develop a systematic approach to differentiate between past resolved infection and potentially transmissible occult disease, guiding crucial management decisions for both maternal and neonatal care.", "problem": "A pregnant patient presents for initial prenatal care. She is a $28$-year-old at $10$ weeks of gestation with no prior documented hepatitis B virus vaccination. Her partner emigrated from a region with high hepatitis B virus prevalence. Screening at the first prenatal visit shows the following serologies: hepatitis B surface antigen (HBsAg) negative, total hepatitis B core antibody (anti-HBc) positive, immunoglobulin M hepatitis B core antibody (IgM anti-HBc) negative, and quantitative hepatitis B surface antibody (anti-HBs) of $6 \\,\\mathrm{mIU/mL}$. Her alanine aminotransferase (ALT) is $22 \\,\\mathrm{U/L}$. She has no symptoms of acute hepatitis. You are asked to determine the most appropriate management plan that distinguishes resolved past infection from occult infection and appropriately addresses vaccination in pregnancy.\n\nUse the following foundational facts and definitions to guide your reasoning:\n\n- HBsAg indicates current hepatitis B virus infection when present and the absence of current infection when absent, acknowledging rare exceptions.\n- Anti-HBc indicates prior exposure to hepatitis B virus; IgM anti-HBc positivity suggests recent or acute infection, whereas isolated total anti-HBc positivity with negative HBsAg can reflect remote resolved infection, a false-positive result, or occult infection.\n- Protective immunity is inferred when anti-HBs is $\\geq 10 \\,\\mathrm{mIU/mL}$; levels $< 10 \\,\\mathrm{mIU/mL}$ indicate susceptibility.\n- Occult hepatitis B virus infection is defined by detectable hepatitis B virus deoxyribonucleic acid (HBV DNA) with negative HBsAg.\n- In pregnancy, hepatitis B virus vaccination is indicated for those without evidence of immunity or infection; recombinant vaccines such as Engerix-B and Recombivax HB are considered acceptable. The two-dose Heplisav-B series lacks sufficient safety data in pregnancy and is not recommended.\n- For newborns, hepatitis B immune globulin (HBIG) and the hepatitis B vaccine birth dose within $12$ hours are indicated when the mother is HBsAg positive; if the mother is HBsAg negative, only the routine birth dose of vaccine is indicated.\n\nWhich of the following management plans is most appropriate for this patient?\n\nA. Order quantitative HBV DNA to assess for occult infection; if HBV DNA is undetectable and anti-HBs remains $< 10 \\,\\mathrm{mIU/mL}$, initiate a $3$-dose hepatitis B vaccination series with a pregnancy-recommended recombinant vaccine (e.g., Engerix-B or Recombivax HB) on a $0$-$1$-$6$ month schedule beginning in pregnancy; do not plan hepatitis B immune globulin (HBIG) for the infant unless maternal HBsAg becomes positive; given ongoing risk, consider post-vaccination anti-HBs testing $1$-$2$ months after series completion.\n\nB. Consider the patient immune based on anti-HBc positivity; defer further testing and vaccination; provide no special newborn measures beyond routine care.\n\nC. Initiate antiviral therapy with tenofovir disoproxil fumarate now to reduce perinatal transmission; HBV DNA testing is unnecessary; administer HBIG to the infant at birth due to maternal anti-HBc positivity.\n\nD. Begin the two-dose Heplisav-B series during pregnancy because anti-HBs is $< 10 \\,\\mathrm{mIU/mL}$; HBV DNA testing is not needed; the infant should receive routine vaccine only.\n\nE. Administer HBIG to the mother now and to the infant at birth due to unclear serology; defer vaccination until postpartum.\n\nSelect the single best option.", "solution": "The patient's clinical and serological data must be systematically interpreted to determine her status and the appropriate course of action for both her and her future newborn.\n\n**Patient Serological Profile Analysis:**\n*   **HBsAg negative:** The patient does not have a current, active hepatitis B infection as typically defined.\n*   **Total anti-HBc positive:** The patient has been exposed to the hepatitis B virus in the past.\n*   **IgM anti-HBc negative:** The exposure was not recent; this rules out an acute or very recent infection.\n*   **anti-HBs of $6 \\,\\mathrm{mIU/mL}$:** The patient lacks protective immunity. The provided foundational facts establish the threshold for protective immunity as anti-HBs $\\geq 10 \\,\\mathrm{mIU/mL}$. Her level of $6 \\,\\mathrm{mIU/mL}$ is below this threshold, indicating susceptibility.\n\nThis serological pattern (HBsAg-negative, anti-HBc-positive, anti-HBs-negative or low-level) is referred to as isolated anti-HBc positivity. According to the provided facts, this can represent three distinct clinical situations:\n1.  **Remote resolved infection:** The patient was infected and cleared the virus, but her protective anti-HBs levels have waned over time.\n2.  **False-positive anti-HBc test:** A possibility, though less likely.\n3.  **Occult hepatitis B virus (HBV) infection:** Defined as the presence of detectable HBV DNA in the blood despite negative HBsAg. This state carries a risk, albeit low, of perinatal transmission.\n\n**Derivation of the Appropriate Management Plan:**\nThe central clinical challenge is to distinguish occult HBV infection from a resolved infection with waning immunity.\n1.  **Diagnostic Clarification:** The definitive test to differentiate these possibilities is a quantitative HBV DNA test. If HBV DNA is detectable, it confirms occult HBV. If HBV DNA is undetectable, it strongly suggests a past resolved infection with loss of protective antibodies, making the patient susceptible to future infection.\n2.  **Vaccination Strategy:**\n    *   If HBV DNA is undetectable, the patient is considered susceptible (anti-HBs $< 10 \\,\\mathrm{mIU/mL}$). Given her ongoing exposure risk (partner from a high-prevalence area), vaccination is indicated.\n    *   The foundational facts state that vaccination is appropriate in pregnancy for susceptible individuals and lists recombinant vaccines (Engerix-B, Recombivax HB) as acceptable. The standard schedule is a $3$-dose series (e.g., at $0$, $1$, and $6$ months), which can be initiated during pregnancy. Heplisav-B is explicitly not recommended.\n    *   To confirm that vaccination has successfully induced immunity, post-vaccination testing for anti-HBs levels $1$ to $2$ months after series completion is a prudent measure, especially with ongoing risk.\n3.  **Newborn Management:**\n    *   The management of the newborn is determined by the mother's HBsAg status. The patient is HBsAg-negative.\n    *   The foundational facts clearly state: \"if the mother is HBsAg negative, only the routine birth dose of vaccine is indicated.\" Therefore, administering hepatitis B immune globulin (HBIG) to the infant is not warranted unless the mother's status were to change to HBsAg-positive.\n\n**Summary of the Correct Plan:**\nThe most appropriate management plan involves ordering an HBV DNA test to rule out occult infection. If negative, the patient should be vaccinated with a pregnancy-safe, $3$-dose recombinant vaccine series. The infant requires only the routine birth dose of the hepatitis B vaccine, without HBIG. Post-vaccination testing for the mother is advisable.\n\n**Evaluation of Options:**\n\n**A. Order quantitative HBV DNA to assess for occult infection; if HBV DNA is undetectable and anti-HBs remains $< 10 \\,\\mathrm{mIU/mL}$, initiate a $3$-dose hepatitis B vaccination series with a pregnancy-recommended recombinant vaccine (e.g., Engerix-B or Recombivax HB) on a $0$-$1$-$6$ month schedule beginning in pregnancy; do not plan hepatitis B immune globulin (HBIG) for the infant unless maternal HBsAg becomes positive; given ongoing risk, consider post-vaccination anti-HBs testing $1$-$2$ months after series completion.**\n*   **Analysis:** This option perfectly aligns with the derived plan. It correctly identifies the need for an HBV DNA test to resolve the diagnostic ambiguity. It proposes the correct course of action (vaccination) for the most likely outcome (susceptibility), specifying the appropriate vaccine type and schedule for pregnancy. It correctly outlines the management for the infant (vaccine only, no HBIG). Finally, it includes the sensible step of post-vaccination testing.\n*   **Verdict:** **Correct**.\n\n**B. Consider the patient immune based on anti-HBc positivity; defer further testing and vaccination; provide no special newborn measures beyond routine care.**\n*   **Analysis:** This option is fundamentally flawed. It incorrectly equates anti-HBc positivity with immunity. Immunity is defined by anti-HBs $\\geq 10 \\,\\mathrm{mIU/mL}$, which this patient does not have. By deferring further testing, it fails to rule out occult HBV. By deferring vaccination, it leaves a susceptible pregnant patient unprotected despite ongoing risk.\n*   **Verdict:** **Incorrect**.\n\n**C. Initiate antiviral therapy with tenofovir disoproxil fumarate now to reduce perinatal transmission; HBV DNA testing is unnecessary; administer HBIG to the infant at birth due to maternal anti-HBc positivity.**\n*   **Analysis:** This option is inappropriate. Antiviral therapy is not indicated for an HBsAg-negative patient without evidence of a high viral load. Declaring HBV DNA testing unnecessary is the opposite of the correct approach. Administering HBIG to the infant is incorrect, as this is reserved for infants of HBsAg-positive mothers.\n*   **Verdict:** **Incorrect**.\n\n**D. Begin the two-dose Heplisav-B series during pregnancy because anti-HBs is $< 10 \\,\\mathrm{mIU/mL}$; HBV DNA testing is not needed; the infant should receive routine vaccine only.**\n*   **Analysis:** This option makes two critical errors. First, it recommends Heplisav-B, a vaccine explicitly stated in the problem's foundational facts as \"not recommended\" in pregnancy due to insufficient safety data. Second, it dismisses HBV DNA testing, failing to address the possibility of occult HBV infection, which is essential for proper management.\n*   **Verdict:** **Incorrect**.\n\n**E. Administer HBIG to the mother now and to the infant at birth due to unclear serology; defer vaccination until postpartum.**\n*   **Analysis:** This option is incorrect. There is no indication for administering HBIG to the mother; it is a post-exposure prophylactic, not a treatment for this serological status. Administering HBIG to the infant is also incorrect, as the mother is HBsAg-negative. Deferring vaccination until postpartum is inappropriate, as safe and effective vaccines are available and recommended for susceptible pregnant women.\n*   **Verdict:** **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "4452674"}, {"introduction": "Beyond individual patient care, modern clinicians must often engage with decisions at the health system level. This exercise [@problem_id:4452677] introduces you to the principles of cost-effectiveness analysis, a key tool in public health policy. You will use a net monetary benefit framework to quantitatively compare two competing strategies for respiratory syncytial virus (RSV) prevention, learning how economic modeling informs resource allocation and the implementation of large-scale immunization programs.", "problem": "A health system is considering two immunization strategies to prevent infant respiratory syncytial virus (RSV) hospitalization during the first RSV season: maternal RSV vaccination during pregnancy versus infant administration of nirsevimab shortly after birth. Assume a single mother–infant dyad is the decision unit, a one-season time horizon, healthcare payer perspective, and no discounting. The following quantities are defined and can be used as the fundamental base:\n\n- Quality-adjusted life year (QALY): a measure that combines length and quality of life; temporary morbidity is converted to QALY loss via disutility.\n- Expected value: if an outcome with disutility $d$ and cost $c$ occurs with probability $p$, the expected QALY loss is $p \\times d$ and the expected cost is $p \\times c$.\n- Willingness-to-pay threshold $\\lambda$: the monetary value per QALY used to convert QALYs to monetary units in a net benefit framework.\n\nUse the standard net monetary benefit framework at willingness-to-pay $\\lambda$ to equate the strategies. All relevant parameters are as follows and apply to the first RSV season:\n\n- Baseline infant RSV hospitalization risk without immunization $p_h = 0.10$.\n- Vaccine effectiveness against hospitalization for maternal RSV vaccination $\\mathrm{VE}_m = 0.50$.\n- Effectiveness against hospitalization for infant nirsevimab $\\mathrm{VE}_n = 0.80$.\n- Direct cost per RSV hospitalization $c_h = 18{,}000$ U.S. dollars.\n- QALY loss per RSV hospitalization $d_h = 0.025$ QALY.\n- Maternal RSV vaccine acquisition price $c_m = 300$ U.S. dollars and administration cost $a_m = 40$ U.S. dollars.\n- Nirsevimab administration cost $a_n = 40$ U.S. dollars.\n- Willingness-to-pay threshold $\\lambda = 100{,}000$ U.S. dollars per QALY.\n\nAssume no other costs or QALY impacts (for example, no immunization-related disutility), and that exactly one of the two strategies is implemented with full uptake. Let $c_n$ denote the nirsevimab acquisition price. Using first principles of expected cost, expected QALY loss, and the net monetary benefit framework at $\\lambda$, determine the value of $c_n$ that makes infant nirsevimab and maternal RSV vaccination yield exactly equal net monetary benefit over the one-season horizon. Express the final answer in U.S. dollars and round your answer to four significant figures.", "solution": "The analysis is based on the Net Monetary Benefit (NMB) framework. The NMB for a given strategy is calculated as the monetized value of the health outcomes (Quality-Adjusted Life Years, or QALYs) minus the total costs.\nFor a strategy $i$, the NMB is given by:\n$$NMB_i = (E[QALY_i] \\times \\lambda) - E[Cost_i]$$\nwhere $E[\\cdot]$ denotes the expected value, and $\\lambda$ is the willingness-to-pay threshold.\n\nThe problem requires finding the nirsevimab acquisition price, $c_n$, such that the NMB of the two strategies are equal. Let the maternal vaccination strategy be denoted by the subscript $m$ and the infant nirsevimab strategy by the subscript $n$.\n$$NMB_m = NMB_n$$\nLet $Q_0$ be the baseline QALYs for an infant without RSV hospitalization. The expected QALYs for a strategy $i$ that results in a probability of hospitalization $p_{h,i}$ is $Q_0 - p_{h,i} d_h$, where $d_h$ is the QALY loss per hospitalization. The expected cost for strategy $i$ is the sum of the intervention cost, $C_{int,i}$, and the expected cost of hospitalization, $p_{h,i} c_h$.\n\nThe NMB for strategy $i$ can be written as:\n$$NMB_i = ((Q_0 - p_{h,i} d_h) \\times \\lambda) - (C_{int,i} + p_{h,i} c_h)$$\n$$NMB_i = Q_0 \\lambda - (C_{int,i} + p_{h,i} c_h + p_{h,i} d_h \\lambda)$$\n$$NMB_i = Q_0 \\lambda - \\left( C_{int,i} + p_{h,i} (c_h + d_h \\lambda) \\right)$$\nThe term $Q_0 \\lambda$ is a constant baseline value for both strategies. Equating $NMB_m$ and $NMB_n$ is therefore equivalent to equating the total monetized costs of each strategy, which include the intervention cost and the monetized expected downstream health-related costs.\nLet $TMC_i$ be the total monetized cost for strategy $i$:\n$$TMC_i = C_{int,i} + p_{h,i} (c_h + d_h \\lambda)$$\nThe indifference condition is $TMC_m = TMC_n$.\n\nFirst, we formulate the total monetized cost for the maternal RSV vaccination strategy, $TMC_m$.\nThe intervention cost is the sum of the vaccine acquisition price and the administration cost:\n$$C_{int,m} = c_m + a_m$$\nThe probability of hospitalization is the baseline risk, $p_h$, reduced by the vaccine effectiveness, $\\mathrm{VE}_m$:\n$$p_{h,m} = p_h (1 - \\mathrm{VE}_m)$$\nSo, the total monetized cost for the maternal vaccination strategy is:\n$$TMC_m = (c_m + a_m) + p_h (1 - \\mathrm{VE}_m) (c_h + d_h \\lambda)$$\n\nNext, we formulate the total monetized cost for the infant nirsevimab strategy, $TMC_n$.\nThe intervention cost is the sum of the nirsevimab acquisition price, $c_n$, and its administration cost, $a_n$:\n$$C_{int,n} = c_n + a_n$$\nThe probability of hospitalization is the baseline risk, $p_h$, reduced by the nirsevimab effectiveness, $\\mathrm{VE}_n$:\n$$p_{h,n} = p_h (1 - \\mathrm{VE}_n)$$\nSo, the total monetized cost for the nirsevimab strategy is:\n$$TMC_n = (c_n + a_n) + p_h (1 - \\mathrm{VE}_n) (c_h + d_h \\lambda)$$\n\nTo find the value of $c_n$ that makes the two strategies equally beneficial, we set $TMC_m = TMC_n$:\n$$(c_m + a_m) + p_h (1 - \\mathrm{VE}_m) (c_h + d_h \\lambda) = (c_n + a_n) + p_h (1 - \\mathrm{VE}_n) (c_h + d_h \\lambda)$$\nWe solve for $c_n$:\n$$c_n = (c_m + a_m - a_n) + p_h (1 - \\mathrm{VE}_m) (c_h + d_h \\lambda) - p_h (1 - \\mathrm{VE}_n) (c_h + d_h \\lambda)$$\n$$c_n = c_m + a_m - a_n + p_h \\left[ (1 - \\mathrm{VE}_m) - (1 - \\mathrm{VE}_n) \\right] (c_h + d_h \\lambda)$$\n$$c_n = c_m + a_m - a_n + p_h (\\mathrm{VE}_n - \\mathrm{VE}_m) (c_h + d_h \\lambda)$$\n\nNow, we substitute the given numerical values into this expression.\nThe parameters are:\n$p_h = 0.10$\n$\\mathrm{VE}_m = 0.50$\n$\\mathrm{VE}_n = 0.80$\n$c_h = 18000$ (U.S. dollars)\n$d_h = 0.025$ (QALY)\n$c_m = 300$ (U.S. dollars)\n$a_m = 40$ (U.S. dollars)\n$a_n = 40$ (U.S. dollars)\n$\\lambda = 100000$ (U.S. dollars per QALY)\n\nFirst, calculate the combined downstream cost per hospitalization, monetized:\n$$c_h + d_h \\lambda = 18000 + (0.025 \\times 100000) = 18000 + 2500 = 20500$$\nNow, substitute all values into the equation for $c_n$:\n$$c_n = 300 + 40 - 40 + 0.10 \\times (0.80 - 0.50) \\times (20500)$$\n$$c_n = 300 + 0.10 \\times (0.30) \\times (20500)$$\n$$c_n = 300 + 0.03 \\times 20500$$\n$$c_n = 300 + 615$$\n$$c_n = 915$$\nThe calculated value for the nirsevimab acquisition price is $915$ U.S. dollars. The problem requires the answer to be rounded to four significant figures. Therefore, the value should be expressed as $915.0$.", "answer": "$$\n\\boxed{915.0}\n$$", "id": "4452677"}]}